Teacher:Given a passage and a query based on the passage, generate an unambiguous, concise and simple answer to the query from information in the passage. Note that the answer may not be present in exact form.
Teacher: Now, understand the problem? Solve this instance: Platelets are the smallest of the three major types of blood cells. 1 Platelets are only about 20% of the diameter of red blood cells. The normal platelet count is 150,000-350,000 per microliter of blood, but since platelets are so small, they make up just a tiny fraction of the blood volume. This news release contains forward-looking statements, including statements related to the potential medical benefits of Soliris ®️ (eculizumab) for the treatment of generalized myasthenia gravis (gMG), and Alexion's future clinical, regulatory and commercial plans for Soliris for the treatment of myasthenia gravis. Seek emergency medical attention or call your doctor right away if you notice any of these symptoms of meningitis: 1 headache and fever with nausea or vomiting; 2 high fever (103 degrees or higher), body aches, flu symptoms; 3 confusion, increased sensitivity to light; or. 4 stiffness in your neck or back. During treatment with eculizumab and for at least 3 months after your last dose, make sure any doctor who treats you knows that you are using this medicine. Eculizumab can have long lasting effects on your body. variable regions. Eculizumab is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa. Eculizumab is produced in a murine myeloma (NS0 cell line) expression system and purified by affinity and ion exchange chromatography. The bulk drug substance manufacturing process also Soliris (eculizumab), produced by US pharma company Alexion, is used to treat patients with paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS). Eculizumab is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells. Eculizumab is a monoclonal antibody. Eculizumab binds to proteins in the blood that can destroy red blood cells in people with genetic conditions that affect the natural defenses of red blood cells. Eculizumab is used to prevent the breakdown of red blood cells in people with paroxysmal nocturnal hemoglobinemia (PNH). You should not use this medication if you have bacterial meningitis or if you have not been vaccinated against meningitis. Tell your doctor if you have a fever or any type of infection. 1 Before starting eculizumab treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). 2 While taking eculizumab, do not receive any kind of immunization or vaccination without your doctor's approval. Patients received meningococcal vaccination prior to receipt of Soliris. In all studies, the dose of eculizumab was 600 mg every 7 2 days for 4 weeks, followed by 900 mg 7 2 days later, then 900 mg every 14 2 days for the study duration. Soliris was administered as an intravenous infusion over 25 45 minutes. The metabolism of eculizumab is thought to occur via lysosomal enzymes that cleave the antibody to generate small peptides and amino acids. The volume of distribution of eculizumab in humans approximates that of plasma. Chemistry. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. It is an immunoglobulin G-kappa (IgG) consisting of human constant regions and murine complementarity-determining regions grafted onto human framework light and heavy chain variable regions. Query: how is eculizumab produced
Student:
Eculizumab is produced in a murine myeloma, NS0 cell line expression system and purified by affinity and ion exchange chromatography.